Semaglutide’s Heart Health Benefits – Beyond Weight Loss
1. Cardiovascular Protection Observed Early
- Studies have shown that semaglutide reduces the risk of major adverse cardiovascular events (MACE)—like heart attacks and strokes—even before patients experience significant weight loss.
- This suggests that the drug may have direct heart-protective effects, beyond its impact on body weight.
2. Key Clinical Trial: SELECT
- The SELECT trial involved over 17,000 participants with established cardiovascular disease and overweight/obesity, but without diabetes.
- Patients on semaglutide experienced a 20% reduction in the risk of cardiovascular events compared to placebo.
- Notably, benefits appeared early in the treatment timeline—before large weight loss occurred.
3. Potential Mechanisms Beyond Weight Loss
Semaglutide’s heart benefits might be due to:
- Anti-inflammatory effects
- Improved endothelial function
- Lowered blood pressure and blood sugar
- Reduced oxidative stress
These effects can all help protect blood vessels and reduce cardiovascular risk independent of weight.
4. Clinical Implications
- This changes how doctors might think about GLP-1 receptor agonists: not just as weight-loss or diabetes drugs, but as cardioprotective agents.
- It could support broader use of semaglutide in people at high cardiovascular risk, even if weight loss is not the primary goal.
0 Comments